Their offering was at 1.3 !!! This POS is down 50% - Total pump n dump scam These clowns got nothing All they wanted to do was dilute and thrive Now no word This POS has lost 70% from high Total pump n dump scam indeed They used the opportunity to dilute the shit out and left you all holding bag Now no update on anything
COVID-19 continues to spread rapidly as governments, hospitals, healthcare workers, and communities reel from the resulting death and economic devastation.
Schools are shut down, college campuses are empty, and many people exhibiting symptoms find it incredibly difficult to get tested. This new strain of coronavirus continues overwhelming and exhausting resources and populations, but there is hope—several organizations are working on COVID-19 research which might help in the creation of treatments, and eventually, a vaccine for the disease.
??This post will be updated as more information becomes available.
FDA Fast Tracks Diagnosis Test The FDA has approved a COVID-19 test that delivers diagnosis results in 45 minutes. Science Alert reports that the “emergency clearance” designation occurred to “make up for lost time” in reference to the glacial pace at which the U.S. has responded to and tried to mitigate the COVID-19 outbreak.
The tests are produced by Cepheid, a California-based biotech company, and won't need to go through a lab for processing but will have limited use. According to Cepheid's Chief Medical Officer, David Persing, “the test should primarily be used in emergency rooms and hospitals, not in doctors’ offices.”
WHO Launches Global Clinical Trials On March 20, the World Health Organization (WHO) announced the launch of a multi-country clinical study called ‘Solidarity.’ This trial will test the effectiveness of four different drugs—remdesivir, chloroquine, a combination of lopinavir and ritonavir, and that combination of lopinavir and ritonavir in conjunction with interferon beta (which helps reduce inflammation)—against COVID-19. According to the announcement, the WHO will “compare [drug] effectiveness to what is called standard of care—the regular support hospitals treating COVID-19 patients use now.”
So far, several countries—Thailand, Argentina, Bahrain, Canada, France, Iran, Norway, South Africa, Spain, and Switzerland—are on board with the Solidarity trial. The U.S. is absent from that list.
AI Takes a Crack at COVID-19 Two of the biggest threats COVID-19 poses include how rapidly and how easily the virus is transmitted. Mitigation efforts so far include social distancing and self-quarantining, but AI has also shown that it could play a role in virus mitigation and treatment creation.
Summit, the world's fastest super computer, used AI to find out which drugs might prevent COVID-19 from spreading to new hosts. The results? Summit discovered that 77 compounds—out of 8,000 that it ran simulations on— might be able to “limit viral recognition of host cells and/or disrupt host-virus interactions,” according to a paper published in ChemRxiv. While this is new information is helpful, it doesn't mean that an effective COVID-19 treatment is right around the corner.
“Our results don't mean that we have found a cure or treatment for the coronavirus,” Jeremy Smith, one of the paper authors and director of the University of Tennessee's Oak Ridge National Laboratory Center for Molecular Biophysics, said.
“We are very hopeful ... that our computational findings will both inform future studies and provide a framework that experimentalists will use to further investigate these compounds. Only then will we know whether any of them exhibit the characteristics needed to mitigate this virus,” Smith adds.
UNMC Tackles COVID-19 Diagnosis & Testing Among the scores of healthcare professionals toiling away to save patients infected with COVID-19 is Jana Broadhurst, director of the Nebraska Biocontainment Unit Clinical Laboratory. Broadhurst told Esquire that her lab is “the beating heart of a novel infectious disease response.” The U.S. only has one federal quarantine center and it sits on the University of Nebraska's Medical Center (UNMC) campus in Omaha. Here, Broadhurst, with the support of her lab team, has spent 20-hour days working on a faster diagnosis kit than the testing procedures set up by the Centers for Disease Control and Prevention (CDC).
And the grueling effort is working. Broadhurst and her team were among the first stateside clinicians to create their own effective diagnosis test. While this UNMC test isn't as fast as Cepheid's, same day results (Broadhurst says it takes four to six hours) are still possible.
A Flu Drug May Treat COVID-19 Favipiravir, an antiviral drug typically used to treat flu patients, may be effective in also treating those who have contracted COVID-19. A member of China's science and technology ministry shared that the drug was used to treat patients in clinical trials in Wuhan, the virus epicenter, and Shenzhen in Guangdong Province.
The patients out of Shenzhen who had tested positive for COVID-19 were retested—on average within a four-day period—after receiving favipiravir. The results came back negative. The Guardian reports that x-rays showed improved lung conditions in 91 percent of those who received favipiravir doses compared the 62 percent who did not receive the drug. Japanese doctors are also using favipiravir on patients who have been diagnosed with COVID-19 and exhibit “mild to moderate symptoms.”
However, it seems that favipiravir—also known as Avigan—is less effective in patients with “more severe symptoms,” per a Japanese health ministry source.
Scientists Pool Their Data Wired reports that staff from the University of North Carolina (UNC) Chapel Hill and the Icahn School of Medicine at Mount Sinai in New York City have teamed up to pool data for patients who have chronic illnesses—with a focus on people with inflammatory bowel disease (IBD) and have contracted COVID-19. These registries include what medications each person takes for their chronic illness and what they've been prescribed for COVID-19 in addition to how the patient responds to treatment.
The registry has been named Secure-IBD (Surveillance Epidemiology of Coronavirus Under Research Exclusion) and went from an idea to launch within a week per Michael Kappelman, a pediatric gastroenterologist at UNC and one of the founders of the registry.
This effort has been a call to action for doctors in other disciplines who have begun working on creating their own international registries including the COVID-19 Global Rheumatology Alliance. This research could help doctors better understand COVID-19, its interactions within different populations who have preexisting conditions. and its interactions with prescription drugs.
Additional Treatments in Progress Stat News reports that several drug companies are working to create treatments and vaccines for COVID-19. They note that Gilead Sciences, Ascletis Pharma, Moderna Therapeutics, and CanSino Biologics are among the groups working on novel medicines to combat COVID-19.
Some of these companies are trying to develop vaccines while others are focusing on virus treatments. So far, no vaccine exists for COVID-19—for a couple of reasons, the main one being that vaccine development can take years. Typically, introducing a vaccine to the public involves three lengthy approval process: licensure, recommendations, and requirements. Licensure is where the FDA needs to approve a new vaccine for use. The Children's Hospital of Philadelphia (CHOP) says that licensure can take decades and notes that the varicella vaccine took 11 years to get FDA licensure.
Recommendation is where healthcare providers “seek the recommendations of the Advisory Committee on Immunization Practices (ACIP), which advises the CDC, the Committee of Infectious Diseases of the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP),” according to CHOP. This is where the FDA compares the risks vs. benefits of the vaccine. Finally, a vaccine reaches the requirements stage. This is where it's determined whether or not a vaccine is required by state legislatures, health departments, and local governments.
Additionally, vaccines must undergo trial phases in which humans and animals alike are used to test the efficacy and effects of the new vaccine. According to CHOP, phase III is the “final stage of development before a company requests product licensing, and it takes three to four years to complete.” So, even with expedited trials and phases and approval processes, a COVID-19 vaccine will still take time.
Market Data 
Markets 
AI
